You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 258 Scientific correlatives from LCCC 1525: a phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials completed
258 Scientific correlatives from LCCC 1525: a phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 202011309
Dec 20202409
Jan 20213004
Feb 20211002
Mar 20215807
Apr 20212803
May 20212005
Jun 2021005
Jul 20210010
Aug 2021005
Sep 2021004
Oct 202140020
Nov 202116010
Dec 20211001
Jan 20221801
Feb 20221601
Mar 20221002
Apr 20222609
May 20221402
Jun 20221401
Jul 20221405
Aug 20222007
Sep 20221202
Oct 2022802
Nov 2022601
Dec 20221601
Jan 2023802
Feb 20231404
Mar 20231602
Apr 20231602
May 20231202
Jun 20231100
Jul 20231003
Aug 2023801
Sep 20231001
Oct 20231002
Nov 20231405
Dec 20233000
Jan 20241400
Feb 20242401
Mar 20242301
Apr 20241402
May 20241600
Jun 20242902
Jul 20241603
Aug 20241803
Sep 20242001
Oct 20242006
Nov 20241002
Dec 20241204
Jan 202520010
Feb 2025203
Mar 2025007
Apr 2025002
May 2025104
Jun 2025003
Total9210206